Ocaratuzumab

History

AME-133v is a humanized IgG1 monoclonal antibody targeting the CD20 antigen on both healthy and malignant B-lymphocytes, engineered at Applied Molecular Evolution. Libraries of antibody Fab (fragment, antigen binding) regions were generated with codon substituted variations of the antibody complementarity determining regions (CDRs) inserted into human antibody light and heavy chain germline frameworks (data on file at Mentrik Biotec). Variants were expressed and selected based on increased binding affinity to CD20 (data on file at Mentrik Biotech). A variable region with increased binding activity for CD20 was selected and developed as AME-133v (data on file at Mentrik Biotech). AME-133v was purchased by Eli Lilly, received the name LY2469298, and a Phase I/II clinical trial in follicular lymphoma was conducted in the U.S. as well as a Phase I clinical trial in rheumatoid arthritis initiated in the U.S. (data shown below). A Phase I clinical trial in follicular lymphoma was also conducted in Japan. AME-133v was purchased by Mentrik, Biotech in 2011 and received the generic name ocaratuzumab from the United States Adopted Name Council in December 2011.

References

References

1. "Statement On A Nonproprietary Name Adopted By The USAN Council - Ocaratuzumab". [[American Medical Association]].
2. (March 2012). "Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma". Clinical Cancer Research.
3. "mentrik.com".
4. (February 2011). "Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma". Cancer Science.